Ultimately, the direct targeting of mitochondria and the simultaneous deregulation of the IGF1R-Akt-mTOR signaling cascade make shikonin a promising compound for the treatment of hematological malignancies. This evidence concerns the gene AKT1 and hematologic disorder.